A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
The participants in this registry study will have fibrodysplasia ossificans progressiva (FOP).
FOP is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (HO)).
HO is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups).
This registry study will take place in countries where the treatment, known as palovarotene, has been approved for use. Participants will either be treated with palovarotene (i.e already be receiving palovarotene as prescribed by their treating physician according to locally approved product information) or untreated with palovarotene.
The main aim of this registry study will be to collect and assess real-world safety data on children and adult participants with FOP treated with palovarotene.
This registry study will also describe the effectiveness of palovarotene in exposed participants, including the effect on everyday activities and physical performance.
In addition, this registry study aims to descriptively compare key safety outcomes (i.e. flare-up episodes, growth outcomes, and bone fractures) between participants exposed and unexposed to palovarotene.
Eligibility
Sex
ALL
Min age
8 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria :
* Adult or child with FOP who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information;
* Signed informed consent as per local regulations must be obtained and maintained. Consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. If applicable, parents or legally authorized representatives must give signed informed consent.
Exclusion Criteria :
* Currently participating in a palovarotene clinical trial;
* Currently participating in any interventional clinical trial for FOP;
* Have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
Primary outcome measure(s)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), whether or not they are considered as related to palovarotene — From Baseline up to 30 days after the last palovarotene dose. Adverse events will be coded according to MedDRA and will be classified by Preferred Term (PT) and system organ class (SOC).
Percentage of Participants With Serious and Non-serious treatment-related TEAEs — From Baseline up to 30 days after the last palovarotene dose. Adverse events will be coded according to MedDRA and will be classified by PT and SOC.
Percentage of Participants With all serious TEAEs, whether or not they are considered as related to the palovarotene — From Baseline up to 30 days after the last palovarotene dose. Adverse events will be coded according to MedDRA and will be classified by PT and SOC.
Percentage of Participants With nonserious TEAEs whether or not they are considered as related to the palovarotene. — From Baseline up to 30 days after the last palovarotene dose. Adverse events will be coded according to MedDRA and will be classified by PT and SOC.
Trial sites (5)
Facility
City
Region
Status
The Regents of the University of California
San Francisco
California
Recruiting
The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine
Philadelphia
Pennsylvania
Recruiting
Edmonton Clinic Health Academy (ECHA)- University of Alberta
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.